Medical/Pharmaceuticals

Delays before patients reach stroke centres remain a major barrier to timely treatment in Malaysia, new report finds

Malaysia experts call for better public awareness of stroke symptoms, standardised hospital imaging protocols and expanded access to specialist care beyond major urban centres KUALA LUMPUR, Malaysia, Sept. 2, 2026 /PRNewswire/ -- Delays occurring before patients reach stroke centres remain a maj...

2026-09-02 15:00 5331

Delays Before Patients Reach Stroke Centers Still Hinder Timely Treatment Across Southeast Asia, Siemens Healthineers Report Finds

New research commissioned by Siemens Healthineers shows transportation delays, slow reporting processes as leading barriers to timely stroke diagnosis. * Stronger referral networks, public awareness, AI-enabled diagnostics, coordinated care are key to strengthening stroke system readiness acros...

2026-09-02 15:00 5204

"From Canine Fat Tissue to Insulin-Producing Cells": Chula Veterinary Researchers Offer New Hope for Diabetes Treatment in Pets

While diabetes is commonly associated with humans, the disease also affects dogs and cats. Its impact on the quality of life of both pets and their owners is often greater than many people realize. BANGKOK, Sept. 2, 2026 /PRNewswire/ -- In dogs, diabetes is similar to Type 1 diabetes in humans, ...

2026-09-02 14:23 3316

Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway

* The Phase 3 BiPASS™ study of Illuccix® and Gozellix® for prostate cancer imaging in the pre-biopsy setting has completed enrollment of 350 patients. * Telix has positively engaged with the FDA on a New Drug Application (NDA) pathway in the U.S. that would support new product reimbursement an...

2026-09-02 09:27 2205

Haier Biomedical Highlights Automated Biostorage and Connected Pharma Solutions at ISPE Singapore 2026

Haier Biomedical Accelerates Its Transformation into an Intelligent Biopharmaceutical Infrastructure Platform at ISPE Singapore 2026 SINGAPORE, Sept. 1, 2026 /PRNewswire/ -- Haier Biomedical  (SHA: 688139) showcased a portfolio of automated and digital solutions sp...

2026-09-01 22:50 3415

Super MOXI® by Sciton Ushers in a New Era of Head-to-Toe Skin Revitalization

PALO ALTO, Calif., Sept. 1, 2026 /PRNewswire/ -- Sciton Inc., a pioneer and leader in medical and aesthetic laser and light-based technologies, today announced the launch of Super MOXI® with High Density (HD) Delivery™, a major evolution of its award-winning MOXI® laser that brings new speed, ver...

2026-09-01 21:10 2893

Suki Named a Transformational Innovation Leader in Ambient Clinical Intelligence by Frost & Sullivan

2026 recognition highlights Suki's innovation, clinical quality and measurable impact as Ambient Clinical Intelligence expands across the enterprise SAN ANTONIO, Sept. 1, 2026 /PRNewswire/ -- Suki

2026-09-01 21:00 1980

Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy

Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction Paxalisib Was Well Tolerated as Monotherapy and in Combination with Checkpoint Inhibition Kazia is Preparing to Advance Pa...

2026-09-01 19:30 2258

Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer

Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity Three-Arm Expansion of the Ongoing TNBC Trial Will Evaluate Paxalisib Plus Fulvestrant, With Palbociclib, Versus Standard-of-Care First Patient Expec...

2026-09-01 19:15 2502

OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel

ROCKVILLE, Md., Sept. 1, 2026 /PRNewswire/ -- OncoC4, Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, today announced the appointment of Steve Chen, JD, PhD, as General Counsel. Dr. Chen brings nearly two decades of lega...

2026-09-01 19:00 2589

JIANGXI BIO Announced 2026 Interim Results

Overseas Contract Orders Reach Nearly RMB27.4 mn and R&D Translation Gains Momentum, with the AEPC Platform Reshaping the R&D Paradigm for Equine Polyclonal Antibody Interim Results Highlights   Key Financial Indicators * Revenue amounted to RMB83.3 mn; gross profit amounted to RMB60.3 mn, ...

2026-09-01 14:44 6427

Siemens Healthineers showcases its AI-powered technological innovations to redefine healthcare delivery in Southeast Asia

* Spotlights how scaling AI and big data can make clinical pathways more efficient * Hosts its second ASEAN CEO Summit to drive collaboration amongst healthcare leaders to redefine care delivery in Southeast Asia * Unveils new regional report "Strengthening Stroke System Readiness Across AS...

2026-09-01 11:00 4202

Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering

Company to host a corporate update call Tuesday, September 1st at 8:00am ET SYDNEY, Sept. 1, 2026 /PRNewswire/ -- Kazia Therapeutics Limited  (NASDAQ: KZIA) ("Kaz...

2026-09-01 07:23 5275

Bausch Health Announces Availability of Solta Medical's Fraxel FTX® in Australia

The next generation in skin resurfacing technology is available to Australian health care practitioners beginning 1 September 2026 LAVAL, QC, Sept. 1, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and its aesthetics busines...

2026-09-01 06:00 2716

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

CS2009 Achieved Key Clinical Validations for Efficacy and Safety As of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the data presented at ASCO in May 2026. With expanded patient...

2026-08-31 20:38 5010

Fosun International Holds 2026 Interim Results Presentation: Unlocking Core Pathways, Accelerating Growth in Industries where we Excel

HONG KONG, Aug. 31, 2026 /PRNewswire/ -- On the morning of 28 August, Fosun International held its 2026 interim results presentation in Hong Kong. This marks Fosun's return to Hong Kong to hold a results presentation for the first time in six years. The results presentation was attended by Guo Gu...

2026-08-31 17:43 4255

SIBIONICS Showcases GS3 in Melbourne, Advancing More Efficient, AI-Powered Glucose Monitoring

MELBOURNE, Australia, Aug. 31, 2026 /PRNewswire/ -- SIBIONICS showcased its sensor innovation and AI-powered glucose monitoring at the joint IDF-WPR, ADC and Metabolic Diseases 2026 congress, held in Melbourne from 18–21 August. Through Booth #1, a scientific symposium and on-site interviews with...

2026-08-31 12:17 1528

Subsidised Access to Columvi® Now Available for Eligible Patients with Relapsed or Refractory DLBCL in Singapore

* Columvi (glofitamab) will be added to the Cancer Drug List (CDL) and Medication Assistance Fund (MAF) on 1 September 2026 for eligible patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for autologous stem cell transplant and have received at lea...

2026-08-31 09:00 2523

Data4Life and Monash Health Announce Strategic Collaboration to Advance Clinical Research

Data4Life and Monash Health have partnered to optimize clinical trial design and execution, complemented by educational workshops and professional training programs, with a shared commitment to improving patient outcomes. - Picture is available at AP

2026-08-31 07:00 1700

Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management

- Expected to enroll approximately 4,600 participants with obesity or overweight across two pivotal trials (AURORA-1 and AURORA-2) in the U.S., Europe, and Canada.  - Global Phase III clinical program to investigate efficacy and safety of three maintenance doses (20 mg, 40 mg, and 60 mg) over 72...

2026-08-30 18:15 3128
1 ... 567891011 ... 380